Arrowstreet Capital’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $23.7M | Sell |
955,315
-661,893
| -41% | -$15.8M | 0.01% | 705 |
|
|
2025
Q4 | $37.7M | Buy |
1,617,208
+312,434
| +24% | +$6.96M | 0.02% | 553 |
|
|
2025
Q3 | $25.7M | Buy |
1,304,774
+81,151
| +7% | +$1.67M | 0.02% | 657 |
|
|
2025
Q2 | $26.6M | Buy |
1,223,623
+188,594
| +18% | +$4.45M | 0.02% | 601 |
|
|
2025
Q1 | $25.1M | Buy |
1,035,029
+336,877
| +48% | +$7.59M | 0.02% | 535 |
|
|
2024
Q4 | $14.6M | Buy |
698,152
+396,506
| +131% | +$8.52M | 0.01% | 708 |
|
|
2024
Q3 | $6M | Buy |
+301,646
| New | +$5.59M | 0.01% | 908 |
|
|
2024
Q2 | – | Sell |
-12,921
| Closed | -$206K | – | 1553 |
|
|
2024
Q1 | $206K | Buy |
+12,921
| New | +$195K | ﹤0.01% | 1579 |
|
|
2023
Q4 | – | Sell |
-144,699
| Closed | -$1.69M | – | 1426 |
|
|
2023
Q3 | $1.69M | Buy |
144,699
+82,744
| +134% | +$1.11M | ﹤0.01% | 886 |
|
|
2023
Q2 | $833K | Sell |
61,955
-105,832
| -63% | -$1.52M | ﹤0.01% | 997 |
|
|
2023
Q1 | $2.78M | Buy |
+167,787
| New | +$2.77M | ﹤0.01% | 841 |
|
|
2022
Q3 | – | Sell |
-19,548
| Closed | -$137K | – | 1295 |
|
|
2022
Q2 | $137K | Sell |
19,548
-295,603
| -94% | -$2.17M | ﹤0.01% | 1181 |
|
|
2022
Q1 | $2.61M | Buy |
315,151
+139,102
| +79% | +$983K | ﹤0.01% | 749 |
|
|
2021
Q4 | $1.19M | Buy |
176,049
+145,249
| +472% | +$955K | ﹤0.01% | 1128 |
|
|
2021
Q3 | $163K | Buy |
+30,800
| New | +$168K | ﹤0.01% | 1522 |
|
|
2021
Q1 | – | Sell |
-295,292
| Closed | -$986K | – | 2282 |
|
|
2020
Q4 | $986K | Buy |
+295,292
| New | +$992K | ﹤0.01% | 1837 |
|
|
2020
Q3 | – | Sell |
-63,400
| Closed | -$293K | – | 2356 |
|
|
2020
Q2 | $293K | Buy |
+63,400
| New | +$285K | ﹤0.01% | 2110 |
|
|
2020
Q1 | – | Sell |
-731,259
| Closed | -$2.74M | – | 1902 |
|
|
2019
Q4 | $2.74M | Buy |
+731,259
| New | +$3.42M | 0.01% | 1042 |
|
Other funds holding CPRX
VCM
DM
VPM